However, in the past decade, several large CV outcome trials have provided data on the efficacy of metformin, glucagon-like peptide-1 (GLP1) receptor agonists (GLP1-RA), and sodium glucose cotransporter 2 inhibitors (SGLT-2i) to reduce major adverse CV and renal events in patients with T2DM [92]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.